{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "52f953c0",
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys, os, pandas as pd\n",
    "from glob import glob\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "a492c550",
   "metadata": {},
   "outputs": [],
   "source": [
    "os.chdir('../..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "d797e96c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# ================== GENERAL IMPORTS ==================\n",
    "import os\n",
    "import json\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "# ================== UTIL FUNCTIONS ==================\n",
    "from utils.embedding import get_context_db, retrieve_context\n",
    "from utils.prompt import get_prompt\n",
    "from llm.run_RAGLLM import run_RAG\n",
    "\n",
    "\n",
    "# ================== MODEL & API IMPORTS ==================\n",
    "from mistralai.client import MistralClient\n",
    "from openai import OpenAI\n",
    "from llm.inference import run_llm\n",
    "import faiss\n",
    "\n",
    "# import from "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "46f6cbe3",
   "metadata": {},
   "outputs": [],
   "source": [
    "#test input\n",
    "report = 'external-validation/panel-sequencing/reports/test/P-0000036.txt'\n",
    "with open(report, 'r') as f:\n",
    "    report = f.read()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "0d99e6c7",
   "metadata": {},
   "outputs": [],
   "source": [
    "# --- existing module state ---\n",
    "_READY = False\n",
    "_CLIENT = None\n",
    "_CONTEXT = None\n",
    "_INDEX = None\n",
    "_MODEL_TYPE = None\n",
    "_MODEL_NAME = None\n",
    "_MODEL_EMBED = None\n",
    "\n",
    "def _cache_paths(embed_name: str, version: str = \"v1\"):\n",
    "    os.makedirs(\"indexes\", exist_ok=True)\n",
    "    return (\n",
    "        f\"indexes/{embed_name}__{version}.faiss\",\n",
    "        f\"indexes/{embed_name}__{version}.context.json\",\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "1b57e5ac",
   "metadata": {},
   "outputs": [],
   "source": [
    "def init(\n",
    "    context_json_path: str = \"data/structured_context_chunks.json\",\n",
    "    model_type: str = \"gpt\",\n",
    "    model_api: str = \"gpt-4o-2024-05-13\",\n",
    "    *,\n",
    "    force_rebuild: bool = False,\n",
    "):\n",
    "    global _READY, _CLIENT, _CONTEXT, _INDEX, _MODEL_TYPE, _MODEL_NAME, _MODEL_EMBED\n",
    "    if _READY:\n",
    "        return\n",
    "\n",
    "    load_dotenv()\n",
    "    if model_type in [\"gpt\", \"gpt_reasoning\"]:\n",
    "        api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "        if not api_key: raise RuntimeError(\"OPENAI_API_KEY not set\")\n",
    "        _CLIENT = OpenAI(api_key=api_key)\n",
    "        _MODEL_EMBED = \"text-embedding-3-small\"\n",
    "    elif model_type in [\"mistral\", \"mistral-7b\"]:\n",
    "        api_key = os.getenv(\"MISTRAL_API_KEY\")\n",
    "        if not api_key: raise RuntimeError(\"MISTRAL_API_KEY not set\")\n",
    "        _CLIENT = MistralClient(api_key=api_key)\n",
    "        _MODEL_EMBED = \"mistral-embed\"\n",
    "    else:\n",
    "        raise ValueError(\"Invalid model_type. Please choose from: mistral-7b, mistral, gpt\")\n",
    "\n",
    "    _MODEL_TYPE = model_type\n",
    "    _MODEL_NAME = model_api\n",
    "\n",
    "    index_path, ctx_path = _cache_paths(_MODEL_EMBED)\n",
    "\n",
    "    if (not force_rebuild) and os.path.exists(index_path) and os.path.exists(ctx_path):\n",
    "        with open(ctx_path, \"r\") as f:\n",
    "            _CONTEXT = json.load(f)\n",
    "        _INDEX = faiss.read_index(index_path)\n",
    "    else:\n",
    "        with open(context_json_path, \"r\") as f:\n",
    "            _CONTEXT = json.load(f)\n",
    "        _INDEX = get_context_db(_CONTEXT, _CLIENT, _MODEL_EMBED)\n",
    "        faiss.write_index(_INDEX, index_path)\n",
    "        with open(ctx_path, \"w\") as f:\n",
    "            json.dump(_CONTEXT, f)\n",
    "\n",
    "    _READY = True\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "6a4db2a3",
   "metadata": {},
   "outputs": [],
   "source": [
    "init(context_json_path=\"data/structured_context_chunks.json\",\n",
    "     model_type=\"gpt\",\n",
    "     model_api=\"gpt-4o-2024-05-13\",\n",
    "     force_rebuild=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "f58d7e4e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: \n",
      "The following is a summarized molecular profile from MSK-IMPACT.\n",
      "Based on this profile, answer with the appropriate treatments for this patient in the format above.\n",
      "Patient ID: P-0000036\n",
      "Age: 68\n",
      "Gender: Female\n",
      "Sample ID: P-0000036-T01-IM3\n",
      "Gene Panel: IMPACT341\n",
      "Cancer Type: Lung Adenocarcinoma\n",
      "Sample Type: Primary\n",
      "Tumor Purity: 30.0%\n",
      "=============\n",
      "DNA Variants:\n",
      "AR c.676T>G (p.L226V) - in 14.000000000000002% of 584 reads\n",
      "ERBB2 c.3044G>A (p.G1015E) - in 42.0% of 354 reads\n",
      "FBXW7 c.336_344del (p.D112_E114del) - in 40.0% of 378 reads\n",
      "IRS1 c.1382A>G (p.E461G) - in 44.0% of 418 reads\n",
      "NOTCH4 c.2443T>G (p.C815G) - in 48.0% of 296 reads\n",
      "TP53 c.991C>T (p.Q331*) - in 6.0% of 311 reads\n",
      "TSHR c.202C>T (p.P68S) - in 50.0% of 516 reads\n",
      "CNA Data:\n",
      "No CNA data found for the specified patient ID.\n",
      "Structural Variants:\n",
      "ROS1 - SLC34A2 (TRANSLOCATION)\n",
      "\n",
      "    \n"
     ]
    }
   ],
   "source": [
    "format_input = \\\n",
    "'''\n",
    "The following is a summarized molecular profile from MSK-IMPACT.\n",
    "Based on this profile, answer with the appropriate treatments for this patient in the format above.\n",
    "{report}\n",
    "'''.format(report=report)\n",
    "prompt = get_prompt(strategy = 0, prompt_chunk= format_input)\n",
    "print(prompt)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "6c5b48f1",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer(\n",
    "    text: str,\n",
    "    strategy: int = 0,\n",
    "    num_vec: int = 10,\n",
    "    max_len: int = 2048,\n",
    "    temp: float = 0.0,\n",
    "    random_seed: int = 2025,\n",
    "    *,\n",
    "    rag = True\n",
    "):\n",
    "    if not _READY:\n",
    "            raise RuntimeError(\"Call init(...) first.\")\n",
    "    if rag:\n",
    "        out, _ = run_RAG(\n",
    "            _CONTEXT,\n",
    "            text,\n",
    "            strategy,\n",
    "            _INDEX,\n",
    "            _CLIENT,\n",
    "            num_vec,\n",
    "            _MODEL_TYPE,\n",
    "            _MODEL_NAME,\n",
    "            _MODEL_EMBED,\n",
    "            max_len,\n",
    "            temp,\n",
    "            random_seed,\n",
    "        )\n",
    "    return out or \"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "e596d99a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    [\"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 20 insertion), and is locally advanced or metastatic disease which has progressed on or after platinum-based chemotherapy., one recommended treatment would be Amivantamab-vmjw + Carboplatin + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. (Citation: Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf. Revised March 2024. Accessed March 4, 2024.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Osimertinib. The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or an exon 21 p.L858R variant, as detected by an FDA-approved test. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: \n",
      "The following is a summarized molecular profile from MSK-IMPACT.\n",
      "Based on this profile, answer with the appropriate treatments for this patient in the format above.\n",
      "Patient ID: P-0000036\n",
      "Age: 68\n",
      "Gender: Female\n",
      "Sample ID: P-0000036-T01-IM3\n",
      "Gene Panel: IMPACT341\n",
      "Cancer Type: Lung Adenocarcinoma\n",
      "Sample Type: Primary\n",
      "Tumor Purity: 30.0%\n",
      "=============\n",
      "DNA Variants:\n",
      "AR c.676T>G (p.L226V) - in 14.000000000000002% of 584 reads\n",
      "ERBB2 c.3044G>A (p.G1015E) - in 42.0% of 354 reads\n",
      "FBXW7 c.336_344del (p.D112_E114del) - in 40.0% of 378 reads\n",
      "IRS1 c.1382A>G (p.E461G) - in 44.0% of 418 reads\n",
      "NOTCH4 c.2443T>G (p.C815G) - in 48.0% of 296 reads\n",
      "TP53 c.991C>T (p.Q331*) - in 6.0% of 311 reads\n",
      "TSHR c.202C>T (p.P68S) - in 50.0% of 516 reads\n",
      "CNA Data:\n",
      "No CNA data found for the specified patient ID.\n",
      "Structural Variants:\n",
      "ROS1 - SLC34A2 (TRANSLOCATION)\n",
      "\n",
      "    \n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Lung Adenocarcinoma\",\n",
      "        \"Disease Phase or Condition\": \"Locally advanced or metastatic\",\n",
      "        \"Drug Name\": \"Entrectinib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"No specific prior treatment or resistance status required\",\n",
      "        \"Genomic Features\": \"ROS1 - SLC34A2 (TRANSLOCATION)\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf\"\n",
      "    }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "print(answer(prompt, strategy=0, rag=True))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ccf140be",
   "metadata": {},
   "source": [
    "each full input is approx 2,500 tokens"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
